How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease?

Piero Ruggenenti; Giuseppe Remuzzi

doi:10.1038/ncpneph0406

Related publications

Article2016

Diets for patients with chronic kidney disease, should we reconsider?

William E. Mitch, Giuseppe Remuzzi

Editorial Material2024

Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?

Bi Huang, Garry McDowell, Anirudh Rao, Professor Gregory Lip

Article2008

New strategies to prevent cardiovascular risk in chronic kidney disease

José Luño, Giuseppe Remuzzi, Bernardo Rodríguez‐Iturbe, Juan Carlos Ayus

Article2005

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

T.-Christian H. Mix, Robert Brenner, Mark E. Cooper, Dick de Zeeuw, Peter Ivanovich, Andrew S. Levey, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans‐Henrik Parving, Brian J.G. Pereira, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Catherine Stehman‐Breen, Robert D. Toto, Marc A. Pfeffer

Article2018

Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease

Gennaro Giustino, Roxana Mehran, Patrick W. Serruys, Joseph F. Sabik, Milan Milojevic, Charles A. Simonton, John D. Puskas, David E. Kandzari, Marie-Claude Morice, David P. Taggart, Anthony Gershlick, Philippe Généreux, Zixuan Zhang, Thomas McAndrew, Björn Redfors, Michael Ragosta, Irving L. Kron, Ovidiu Dressler, Martin B. Leon, Stuart J. Pocock, Ori Ben‐Yehuda, A. Pieter Kappetein, Gregg W. Stone

Journal of the American College of Cardiology